Application of Radionuclides and Antibody -Drug Conjugates to Target Cancer
DOI:
https://doi.org/10.17140/CSMMOJ-1-102Keywords:
Targeted alpha therapy, Radionuclide therapy, Antibody-drug conjugates, Monoclonal antibody, Alpharadin®, Xofigo®, Bexxar®, Zevalin®, Adcetris®, KadcylaAbstract
Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilisation of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in the form of alpha or beta particles to bind onto antigen specific cancer cells initiating apoptosis. This inaugural article aims to deliver a brief account of these targeted therapies in the treatment of oncological disease states such as leukaemia, non-Hodgkin’s lymphoma, neuroendocrine tumours, breast cancer and prostate cancer bone metastases.
References
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8(6): 473-480. doi: 10.1038/nrc2394
Kitson SL, Quinn DJ, Moody TS, Speed D, Watters W, Roz-zell D. Antibody-drug conjugates (ADCs) - A new generation of biotherapeutic bullets. Chim Oggi. 2013; 31(4): 30-36.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517): 495-497.
Steiner M, Neri D. Antibody-radioniclide conjugates for can-cer therapy: historical consideration and new trends. Clin Cancer Res. 2011; 17(20): 6406-6416. doi: 10.1158/1078-0432.CCR-11-0483
Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013; 81(1): 113-121. doi: 10.1111/cbdd.12085
Sievers EL, Senter PD. Antibody-drug conjugates in can-cer therapy. Annu Rev Med. 2013; 64: 15-29. doi: 10.1146/ annurev-med-050311-201823
Rahman KM, James CH, Thurston DE. Effect of base se-quence on the DNA cross-linking properties of pyrroloben-zodiazepine (PBD) dimers. Nucleic acid Res. 2011; 39(13): 5800-5812. doi: 10.1093/nar/gkr122
Kitson SL, Cuccurullo V, Ciarmiello A, Salvo D, Mansi L. Clinical applications of positron emission tomogra-phy (PET) imaging in medicine: oncology, brain diseases and cardiology. Curr Radiopharm. 2009; 2: 224-253. doi: 10.2174/1874471010902040224
Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging. 2012; 39(10): 1519-1524. doi: 10.1007/s00259-012-2185-x
Winter G, Harris WJ. Humanized antibodies. Trends Phar-macol Sci. 1993; 14(5): 139-143.
Vegt E, Jong de M, Wetzels JMF, et al. Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Preven-tion. J Nucl Med. 2010; 51(7): 1049-1058. doi: 10.2967/ jnumed.110.075101
Paganelli G, Bartolomei M, Ferrari M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001; 16(3): 227-235. doi: 10.1089/10849780152389410
Palm S, Elgqvist J, Jacobsson L. Patient-specific alpha-particle dosimetry. Curr Radiopharm. 2011; 4(4): 329-335. doi: 10.2174/1874471011104040329
Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm. 2011; 4(3): 261- 265. doi: 10.2174/1874471011104030261
Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clin-ical applications of newer radionuclide therapies. Eur J Can-cer. 2006; 42(8): 994-1003. doi: http://dx.doi.org/10.1016/j. ejca.2005.12.020
Lindegren S, Frost SH. Pretargeted radioimmunotherapy with α-particle emitting radionuclides. Curr Radiopharm. 2011; 4(3): 248-260. doi: 10.2174/1874471011104030248
Miao Y, Hylarides M, Fisher DR, et al. Melanoma therapy via peptide-targeted (alpha)-radiation. Clin Cancer Res. 2005; 11(15): 5616-5621. doi: 10.1158/1078-0432.CCR-05-0619
Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011; 52(6): 841-844. doi: 10.2967/jnumed.110.084236
Wang L, Tang K, Zhang Qi, et al. Somatostatin recep-tor-based molecular imaging and therapy for neuroendo-crine tumors. BioMed Research International. 2013. doi: 10.2174/1568009053202054
Morgenstern A, Bruchertseifer F, Apostolidis C. Targeted al-pha therapy with 213Bi. Curr Radiopharm. 2011; 4(4): 295-305. doi: 10.2174/1874471011104040295
Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radio-therapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Design. 2000; 6(14): 1433-1455. doi: 10.2174/1381612003399275
Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011; 4(4): 306-320. doi: 10.2174/1874471011104040306
Ogawa K, Washiyama K. Bone target radiotracers for pallia-tive therapy of bone metastases. Curr Med Chem. 2012; 19(20): 3290-3300. doi: 10.2174/092986712801215865
Salvatori M, Indovina L, Mansi L. Targeted α-particle thera-py: a clinical overview. Curr Radiopharm. 2008; 1(3): 251-253. doi: 10.2174/1874471010801030251
El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-Targeted therapies in metastatic castration-resistant pros-tate cancer: Evolving Paradigms. Prostate Cancer. 2013. doi: 10.1155/2013/210686
Jadvar H, Quinn DI. Targeted α-particle therapy of bone me-tastases in prostate cancer. Clin Nucl Med. 2013; 38(12): 966- 971. doi: 10.1097/RLU.0000000000000290
Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009; 10(12): 1346- 1358.
U.S. Food and Drug AdministrationPress Release. FDA ap-proves new drug for advanced prostate cancer. Website: http:// www.fda.gov/newsevents/newsroom/pressannouncements/ ucm352363.htm 2013; Accessed March 15, 2014.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213-223. doi: 10.1056/NEJMoa1213755
Sartor O, Maalouf BN, Hauck CR, Macklis RM. Targeted use of Alpha Particles: Current Status in Cancer Therapeutics. J Nucl Med Radiat Ther. 2012; 3: 136. doi: 10.4172/2155- 9619.1000136
Carroll V, Demoin DW, Hoffman TJ, Jurisson SS. Inorganic chemistry in nuclear imaging and radiotherapy: current and fu-ture directions. Radiochimica Acta. 2012; 100: 653-667. doi: 10.1524/ract.2012.1964
Fisher DR. Commercial availability of alpha-emitting radio nuclides for medicine. Curr Radiopharm. 2008; 1: 127-134. doi: 10.2174/1874471010801030127
Kassis AI, Adelstein SJ. Radiobiologic principles in radio-nuclide Therapy. J Nucl Med. 2005; 46(Suppl): 4S-12S.
Unak P. Targeted tumour radiotherapy. Brazilian Archives of Biology and Technology. 2002; 45: 97-110. doi: http://dx.doi. org/10.1590/S1516-89132002000500014
Regaud C, Lacassagne A. La radiosensibilite cellulaire en-visage dans ses manifestations generalis. In- Radiophysiologie et radiotherapie, Paris. Archieves de L’Institut du Radium de L’Universite de Paris and La Foundation Curie. 1927; 95-116.
Dahle J, Abbas N, Bruland ØS, Larsen RH. Toxicity and relative biological effectiveness of alpha emitting radioim-mumoconjugates. Curr Radiopharm. 2011; 4(4): 321-328. doi: 10.2174/1874471011104040321
Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Peptide imaging with somatostatin analogues: more than cancer probes. Curr Radiopharm. 2013; 6(1): 36-40. doi: 10.2174/1874471011306010006
Cuccurullo V, Mansi L. Toward tailored medicine (and be-yond): the phaeochromocytoma and paraganglioma model. Eur J Nucl Med Mol Imaging. 2012; 39(8): 1262-1265. doi: 10.1007/ s00259-012-2156-2
Jurcic GJ, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukaemia. Blood. 2002; 100(4): 1233-1239.
Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients; pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2 -a phase I study. J Nucl Med. 2009; 50(7): 1153-1160.
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013; 5: 1-14. doi: 10.2147/CMAR.S25537
de Bruyn M, Rybczynska AA, Wei Y, et al. Melanoma-as-sociated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma out-growth in vitro and in vivo. Mol Cancer. 2010; 9: 301. doi: 10.1186/1476-4598-9-301
Maloney DG. Anti-CD20 antibody therapy for B-cell lym-phomas. N Engl J Med. 2012; 366(21): 2008-2016. doi: 10.1056/ NEJMct1114348
Zalutsky MR, Reardon DA, Akabani G, et al. Clinical ex-perience with α-particle-emitting 211 At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008; 49(1): 30-38. doi: 10.2967/jnumed.107.046938
Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, et al. (2011) Anti-MUC1 monoclonal antibody (C595) and doce taxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo Ovarian Cancer Model. PLoS ONE. 6(9): e24405. doi: 10.1371/journal.pone.0024405
Allen BJ, Tian Z, Rizvi SMA, Li Y, Ranson M. Preclinical stiudies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Brit J Cancer. 2003; 88(6): 944-950. doi: 10.1038/sj.bjc.6600838
Smith-Jones PM, Vallabhajosula, S, Navarro, V, Bastidas, D, Goldsmith, SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the Extracellular domain of prostate-specific mem-brane antigen: preclinical studies in nude mice bearing LNCaP Human Prostate Tumor. J Nucl Med. 2003; 44(4): 610-617.
Cohen MH, Shen Y Li, Keegan P, Pazdur R. FDA drug ap-proval summary: bevacizumab (Avastin) as treatment of recur-rent glioblastoma multiforme. Oncologist. 2009; 14(11): 1131- 1138. doi: 10.1634/theoncologist.2009-0121
Mayes S, Brown N, Illidge TM. New antibody drug treat-ments for lymphoma. Expert Opin Biol Ther. 2011; 11(5): 623- 640. doi: 10.1517/14712598.2011.560569
Lin FI, Iagaru A. Current concepts and future directions in radioimmunotherapy. Curr Drug Discov Technol. 2010; 7(4): 253-262. doi: 10.2174/157016310793360684
Kitson SL, Cuccurullo V, Moody TS, Mansi L. Ra-dionuclide antibody-conjugates, a targeted therapy to-wards cancer. Curr Radiopharm. 2013; 6(2): 57-71. doi: 10.2174/1874471011306020001
Otte A. Diagnostic imaging prior to 90Y-ibritumomab tiux-etan (Zevalin) treatment in follicular non-Hodgkin’s lymphoma. Hell J Nucl Med. 2008; 11(1): 12-15.
Cicone F, Baldini R, Cox MC, et al. Radioimmunotherapy of heavily pre-treated, non-Hodgkin’s lymphoma patients: efficacy and safety in a routine setting. Anticancer Res. 2009; 29(11): 4771-4778.
Mace JR. Radioimmunotherapy in follicular lymphoma: an update. Clin Ad. Hematol Oncol. 2012; 10(6): 394-396.
Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011; 17(20): 6389- 6397. doi: 10.1158/1078-0432.CCR-11-1417
U.S. Food and Drug AdministrationPress Release. FDA ap-proves Adcetris to treat two types of lymphoma. Website: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm268781.htm 2011; Accessed March 15, 2014.
FDA approves new treatment for late-stage breast cancer: http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm340704.htm 2013; Accessed March 15, 2014.
Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to pri-mary effusion lymphoma. Blood. 2013; 122(7): 1233-1242. doi: 10.1182/blood-2013-01-481713
Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7): 631-637. doi: 10.1038/nbt.2289
Nolting B. Linker technologies for antibody-drug conjugates. Methods Mol Biol. 2013; 1045: 71-100. doi: 10.1007/978-1- 62703-541-5_5
Beck A, Lambert J, Sun M, Lin K. Fourth world antibody-drug conjugate summit: February 29-March 1, 2012, Frank-furt, Germany. MAbs. 2012; 4(6): 637-647. doi: 10.4161/ mabs.21697
Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components.Toxins (Basel). 2011; 3(7): 848-883.
Ducry L, Stump B. Antibody-drug conjugates: linking cyto-toxic payloads to monoclonal antibodies. Bioconjugate Chem. 2010; 21(1): 5-13. doi: 10.1021/bc9002019
Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21(7): 778-784. doi: 10.1038/ nbt832
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011; 17(20): 6437-6447. doi: 10.1158/1078-0432.CCR-11-0762
Kozak KR, Tsai SP, Fourie-O’Donohue A, et al. Total anti-body quantification for MMAE-conjugated antibody-drug con-jugates: impact of assay format and reagents. Bioconjug Chem. 2013; 24(5): 772-779. doi: 10.1021/bc300491k
Tijink BM, Buter J, De Bree R, et al. A Phase I dose escala-tion study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006; 12(20): 6064-6072. doi: 10.1158/1078-0432.CCR-06-0910
Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clini-cal pipeline review. Methods Mol Biol. 2013; 1045: 1-27. doi: 10.1007/978-1-62703-541-5_1
Ouyang J. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Meth-ods Mol Biol. 2013; 1045: 275-283. doi: 10.1007/978-1-62703- 541-5_17
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
